Randomized phase 2 study of 3 therapeutic modalities in PS [performance status] 2/3 patients with NSCLC [non-small cell lung cancer] stage IIIB/IV.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Gefitinib; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Apr 2010 Biomarkers information updated
- 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2008 Results have been presented at ASCO 2008.